“a favorable trend”

p53 expression and AFTV efficacy AFTV therapy showed significantly greater efficacy in p53-negative cases, particularly with respect to overall survival ( p = 0.03), while progression-free survival showed a favorable trend ( p = 0.07).

3.1.5 Biomarker sub-studies There were no significant differences between simufilam and placebo for changes from baseline to Week 52 or Week 76 on tertiary endpoints of sub-studies for plasma biomarkers in either trial ( n = 27–47 per group; Table 2 ), although there was a favorable trend on plasma GFAP, a neuroinflammation marker, in the 100 mg group in REFOCUS ( p = 0.07).

Although PFS demonstrated a favorable trend, the difference was not statistically significant (9.7 vs. 8.3 months, P=0.07).

Consistent with our original report, there was a favorable trend to improved OS with melanoma cognate help (HR 0.64, 95% CI: 0.40–1.04, P = 0.07, Addendum Figure 1A; original report: HR 0.65, 95% CI: 0.40–1.05, P = 0.08), with delayed separation of the curves starting at 2.5 years and progressive widening of the curves such that the OS estimate for the 12MP + 6MHP regimen exceeded the upper bound of the 95% CI of the OS estimate for the 12MP+tet regimen at 8 years (Addendum Figure 1B).

Also, Kaplan–Meier curves for time to treatment failure (i.e., time to first emetic event or use of rescue medication) showed a separation after 96 h, with a favorable trend in the fosnetupitant group (hazard ratio 0.789; 95% CI 0.610, 1.021; P = 0.071).

12 A favorable trend toward cemiplimab was also observed in TTD analysis of GHS/QoL for the overall population (HR, 0.70; 95% CI, 0.48–1.04; p = .0725). 6 Change from baseline in GHS/QoL scores by disease progression and objective response For the two treatment arms combined (the overall population), GHS/QoL scor

Of the latter, dietary knowledge/behavior (+1.60) and quality of life (+1.83) improved ( P < 0.0001), with a favorable trend for physical activity (+0.06, P = 0.0756).

In the BRAF V600E cohort, the mPFS showed a favorable trend for the GMT ( n = 62, median 9.2 months, 95% CI 5.8-17.0 months) versus the non-GMT group ( n = 20, median 4.2 months, 95% CI 2.3 months-NE, P = 0.076, HR 0.59, 95% CI 0.33-1.06).

In the ITT population, Cerebrolysin set a favorable trend to lower any HT with a rate of 15.9% versus 23.3% in the control group and a corresponding OR of 0.543 (95% CI: 0.281–1.05; p = 0.078).

There were also increased responses toward FABP7 and SNAP91, but only significant compared to one of the control cohorts (FABP7 MS versus HC and SNAP91 MS versus OND), while the respective remaining groups showed a favorable trend: FABP7 MS versus OND ( P = 0.079) and SNAP91 MS versus HCs ( P = 0.112).

At the first interim analysis, there was also a favorable trend in overall survival (OS) (21.3 vs 17.6 months; p = 0.08), which became significant in the PD-L1-positive subgroup in favor of the experimental arm (25.0 vs 15.5 months) [ 14 ].

A favorable trend in PFS was also observed (P = 0.08; HR = 0.62, 95% CI: 0.36–1.07) ( Supplementary Figure 2A ).

The intention-to-treat analysis demonstrated a favorable trend with high-dose edoxaban (1.57% high-dose edoxaban versus 1.8% warfarin; p = 0.08) and an unfavorable trend with low-dose edoxaban (2.04% low-dose edoxaban; p = 0.10).

Regarding OS, endocrine disorder demonstrated a statistically significant association with better outcomes (P=0.02, Figure 2B ), while rash did not reach statistical significance; however, it showed a favorable trend (P=0.08, Figure 2C ).

4 ) and a favorable trend towards larger FBM loss (MD = -1.22, 95% CI: -2.59 to 0.15, p = 0.08, I 2 = 0%, Fig. 5 ) in overweight and/or obese populations.

IVT showed a favorable trend for early neurological recovery ( p = 0.081) but was not independently associated with functional outcome ( p = 0.380).

Although the difference among the three groups did not reach statistical significance, a favorable trend was observed ( p = 0.0816), consistent with the findings from the primary analysis (Table 3 ).

While the group-by-time interaction for sleep quality was not significant, a favorable trend toward within-group improvement was observed in the HIIT group (− 0.57 points, − 12.15%, p = 0.082, d = 0.270), whereas no such trend occurred in the control group (0.07 points, 1.28%, p = 0.892, d = 0.029).

Given this premise, they found a favorable trend for systemic treatment compared to RT in the inoperable group ( p = 0.083).

There was a favorable trend ( P = 0.086; Fig. 3E ) for those of Asian heritage, but the sample size was insufficient for a significant linkage.

19.2%), however, we could observe a favorable trend in the DK culotte group in terms of TLF ( p = 0.086).

In addition, a favorable trend of overall survival (hazard ratio 0.80; 95% CI, 0.57–1.11; P = .0867) and a significantly better objective response rate (TACE plus pembrolizumab + Len, 71.3%; TACE + placebo, 49.8%; P < .0001) were also reported for TACE plus pembrolizumab + Len.

The estimated 7-year OS was 96% in the cohort of patients with a stable MR4.5 and 89% in the cohort of patients who did not reach such a response, with a favorable trend that has so far not reached statistical significance ( p = 0.087).

In addition, a favorable trend toward improved OS was observed when comparing MFR plus denosumab with SS plus denosumab (HR = 0.34, 95% CI: 0.10–1.18, P = 0.088), although this did not reach statistical significance (Fig. 2 B).

The rate of serious complications was statistically similar between the groups, albeit a favorable trend was noted among patients who underwent MIE (58% for the OE group vs 42% for MIE group; 2-sided P = .089; 1-sided P = .059 for MIE superiority).